These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 20944071)

  • 1. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.
    Walker BA; Wardell CP; Chiecchio L; Smith EM; Boyd KD; Neri A; Davies FE; Ross FM; Morgan GJ
    Blood; 2011 Jan; 117(2):553-62. PubMed ID: 20944071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors.
    Salhia B; Baker A; Ahmann G; Auclair D; Fonseca R; Carpten J
    Cancer Res; 2010 Sep; 70(17):6934-44. PubMed ID: 20736376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.
    Schmidt-Hieber M; Gutiérrez ML; Pérez-Andrés M; Paiva B; Rasillo A; Tabernero MD; Sayagués JM; Lopez A; Bárcena P; Sanchez ML; Gutiérrez NC; San Miguel JF; Orfao A
    Haematologica; 2013 Feb; 98(2):279-87. PubMed ID: 22929983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chemotherapy for multiple myeloma].
    Ishida T
    Nihon Rinsho; 2007 Dec; 65(12):2280-4. PubMed ID: 18069273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
    An G; Li Z; Tai YT; Acharya C; Li Q; Qin X; Yi S; Xu Y; Feng X; Li C; Zhao J; Shi L; Zang M; Deng S; Sui W; Hao M; Zou D; Zhao Y; Qi J; Cheng T; Ru K; Wang J; Anderson KC; Qiu L
    Clin Cancer Res; 2015 May; 21(9):2148-56. PubMed ID: 25652456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
    Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
    Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment strategies for plasma cell myeloma.
    Smith L; Alexanian R
    CA Cancer J Clin; 1985; 35(4):214-20. PubMed ID: 3926257
    [No Abstract]   [Full Text] [Related]  

  • 9. [New treatment strategies for multiple myeloma].
    Ozaki S
    Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
    [No Abstract]   [Full Text] [Related]  

  • 10. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents.
    Kuroda Y; Sakai A; Okikawa Y; Munemasa S; Katayama Y; Hyodo H; Imagawa J; Takimoto Y; Okita H; Ohtaki M; Kimura A
    Int J Hematol; 2005 May; 81(4):335-41. PubMed ID: 15914366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias.
    Zou D; An G; Zhu G; Wang J; Shi L; Meng H; Xu Y; Sui W; Deng S; Zhan F; Qiu L
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):319-25. PubMed ID: 24296491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etoposide and ifosfamide for MP (melphalan and prednisolone)- and VAD (vincristine, adriamycin and dexamethasone)-resistant plasma cell myeloma: a case report.
    Ikeda K; Abe N; Morioka A; Inoo M; Nagai M; Kubota Y; Irino S
    Jpn J Med; 1990; 29(5):516-8. PubMed ID: 2089176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.
    Mikulasova A; Wardell CP; Murison A; Boyle EM; Jackson GH; Smetana J; Kufova Z; Pour L; Sandecka V; Almasi M; Vsianska P; Gregora E; Kuglik P; Hajek R; Davies FE; Morgan GJ; Walker BA
    Haematologica; 2017 Sep; 102(9):1617-1625. PubMed ID: 28550183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance.
    Stanganelli C; Arbelbide J; Fantl DB; Corrado C; Slavutsky I
    Ann Hematol; 2010 Feb; 89(2):191-9. PubMed ID: 19727727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in the distribution of cytogenetic subtypes between multiple myeloma patients with and without a family history of monoclonal gammopathy and multiple myeloma.
    Greenberg AJ; Cousin M; Kumar S; Ketterling RP; Knudson RA; Larson D; Colby C; Scott C; Vachon CM; Vincent Rajkumar S
    Eur J Haematol; 2013 Sep; 91(3):193-195. PubMed ID: 23647020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients.
    Brousseau M; Leleu X; Gerard J; Gastinne T; Godon A; Genevieve F; Dib M; Lai JL; Facon T; Zandecki M;
    Clin Cancer Res; 2007 Oct; 13(20):6026-31. PubMed ID: 17947464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Heterogenicity of the response to chemotherapy in plasmablastic myeloma].
    Paule B; Quillard J; Bisson M; Massias P
    Nouv Rev Fr Hematol (1978); 1987; 29(6):391-6. PubMed ID: 2454453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics.
    Roy Choudhury S; Byrum SD; Alkam D; Ashby C; Zhan F; Tackett AJ; Van Rhee F
    Clin Epigenetics; 2023 Feb; 15(1):18. PubMed ID: 36737807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology and therapy of multiple myeloma.
    Barlogie B; Alexanian R
    Acta Haematol; 1987; 78 Suppl 1():171-4. PubMed ID: 3124442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.